About the project

The UNLOOC project tackles the challenge inherent in animal testing of drugs, aiming to demonstrate through its five novel use cases how the groundbreaking methods using Organ-on-a-Chip (OOC) technology enable the development of more effective treatments, leaving animal subjects out of the equation. The OOC technology to be developed in the UNLOOC project will not only enable controlled drug testing, but also the modelling of disease pathophysiology.

UNLOOC use cases

  • Use case 1: Human diversity panel

    Developing human OOC diversity panels and demonstrating the impact in the drug efficacy and safety testing using advanced multi-parametric AI-based analysis.

    This use case is led by InSphero AG (Switzerland).

  • Use case 2a: SOMP for epithelium-on-chip

    Standardized Single-Organ Smart OOC Multi-well Plate (SOMP) evaluated with epithelium-on-chip and cancer-on-chip.

    This use case is led by Multi Channel Systems MCS GmbH (Germany).

  • Use case 2b: Multi-organ multi-well plate

    Standardized Multi-Organ Multi-well Plate (MOMP) with integrated non-invasive sensing to enable the prediction of oral drug absorption.

    This use case is led by Nederlandse Organisatie voor toegepast-natuurwetenschappelijk onderzoek TNO (the Netherlands).

  • Use case 3: Skin-on-Chip

    Skin-on-Chip for Pharma Applications and Chemical Compound Testing: Designing a skin-on-chip-system to assess transdermal drug delivery, skin penetration, absorbance, and toxicity validated in a toxicity and drug delivery scenario.

    This use case is led by Microfluidic ChipShop GmbH (Germany).

  • Use case 4: BBB-on-Chip

    Integrated fluidic control, sensing, and incubation system for the BBB-on-Chip: Designing a blood brain barrier (BBB) platform that is affordable for biomedical research labs and scalable for contract research organisations (CROs).

    This use case is led by BEOnChip S.L. (Spain).

  • Use case 5: Lung-on-Chip

    Developing an advanced lung-on-a-chip platform to better assess the safety of new drug candidates.

    This use case is led by Alveolix AG (Switzerland).